Valiant Capital reports 5.1% stake in Core Scientific
Valiant Capital Management filed an amendment on Schedule 13G reporting beneficial ownership of 16,213,103 shares of Core Scientific, Inc. common stock, equal to 5.1% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Valiant Capital Management filed an amendment on Schedule 13G reporting beneficial ownership of 16,213,103 shares of Core Scientific, Inc. common stock, equal to 5.1% of the class. The percentage is calculated using 317,885,292 shares outstanding as of May 1, 2026. The filing states the holding is reported jointly by Valiant Capital Management, L.P., Valiant Capital Management, LLC and Christopher R. Hansen, with shared voting and shared dispositive power over the 16,213,103 shares. The reporting persons disclaim membership in a group and disclaim beneficial ownership except to the extent of pecuniary interest. Signatures are dated May 15, 2026.
Insights
Filing documents a passive, joint reporting stake near the 5% disclosure threshold.
The amendment records 16,213,103 shares and identifies shared voting and dispositive power among VCM entities and Christopher R. Hansen. The filing explicitly disclaims acting as a group while stating shared powers and a pecuniary interest in the Funds.
Watch subsequent amendments or Schedule 13D filings for any change in intent or control; timing of any such shift is not disclosed here.
Holding equals 5.1% of outstanding shares as calculated in the filing.
The reported stake uses an outstanding share base of 317,885,292, yielding the 5.1% figure. The Funds are named as beneficial holders while individual fund-level holdings are stated to be below 5% each.
Market impact depends on trading by those funds or additional disclosures; the amendment itself is a positional disclosure without stated plan or sale activity.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficially owned regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.